FGF23-regulated production of Fetuin-A (AHSG) in osteocytes

D. Mattinzoli, M. P. Rastaldi, M. Ikehata, S. Armelloni, C. Pignatari, L. A. Giardino, M. Li, C. M. Alfieri, A. Regalia, D. Riccardi, P. Messa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: AHSG, a serum glycoprotein with recognized anti-calcification activity, has also been suggested to modulate both bone formation and resorption. Though the bulk of AHSG is mostly synthesized in the liver, it has been claimed that also bone cells might produce it. However, the extent of the bone AHSG production and the potential controlling factors remain to be definitively proven.A relevant number of studies support the notion that FGF23, a bone-derived hormone, not only regulates the most important mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, etc.), but might be also involved in cardiovascular (CV) outcome, both in chronic kidney disease (CKD) patients and in the general population. Furthermore, in addition to some direct autocrine and paracrine effects in bone, FGF23 has been suggested to interact with AHSG. In this study we investigated if AHSG is really produced by bone cells, and if its bone production is related and/or controlled by FGF23, using cultured bone cells, according to a new method recently published by our group. Results: Our data show that AHSG is consistently produced in osteocytes and to a far lesser extent in osteoblasts. Both FGF23 addition to the culture medium and its over-expression in osteocytes were associated with a consistent increase of both AHSG mRNA and protein, while FGF23 silencing was followed by opposite effects. Though most of these results were largely affected by the blockage of FGF23 receptors, the role of these receptors in the different experimental sets is still not completely clarified. In addition, we found that FGF23 and AHSG proteins co-localized both in cytoplasm and nucleus, which suggests a possible reciprocal interactivity. Conclusions: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is modulated by FGF23. Since both proteins play important roles in the bone and cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and vascular pathology, in particular in CKD patients, prompting future investigations in this field.

Original languageEnglish
Pages (from-to)35-47
Number of pages13
JournalBone
Volume83
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

alpha-2-HS-Glycoprotein
Osteocytes
Bone and Bones
Chronic Renal Insufficiency
Pathology
Bone Resorption
Parathyroid Hormone
Osteoblasts
Osteogenesis
Vitamin D
Minerals
Blood Vessels
Culture Media
Cultured Cells
Glycoproteins
Cytoplasm

Keywords

  • AHSG
  • Chronic kidney disease
  • FGF receptor
  • FGF23
  • Osteocyte
  • Vascular calcification

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

FGF23-regulated production of Fetuin-A (AHSG) in osteocytes. / Mattinzoli, D.; Rastaldi, M. P.; Ikehata, M.; Armelloni, S.; Pignatari, C.; Giardino, L. A.; Li, M.; Alfieri, C. M.; Regalia, A.; Riccardi, D.; Messa, P.

In: Bone, Vol. 83, 01.02.2016, p. 35-47.

Research output: Contribution to journalArticle

@article{26d64fb9f2bc4ee8b2e4ff30953e44a1,
title = "FGF23-regulated production of Fetuin-A (AHSG) in osteocytes",
abstract = "Introduction: AHSG, a serum glycoprotein with recognized anti-calcification activity, has also been suggested to modulate both bone formation and resorption. Though the bulk of AHSG is mostly synthesized in the liver, it has been claimed that also bone cells might produce it. However, the extent of the bone AHSG production and the potential controlling factors remain to be definitively proven.A relevant number of studies support the notion that FGF23, a bone-derived hormone, not only regulates the most important mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, etc.), but might be also involved in cardiovascular (CV) outcome, both in chronic kidney disease (CKD) patients and in the general population. Furthermore, in addition to some direct autocrine and paracrine effects in bone, FGF23 has been suggested to interact with AHSG. In this study we investigated if AHSG is really produced by bone cells, and if its bone production is related and/or controlled by FGF23, using cultured bone cells, according to a new method recently published by our group. Results: Our data show that AHSG is consistently produced in osteocytes and to a far lesser extent in osteoblasts. Both FGF23 addition to the culture medium and its over-expression in osteocytes were associated with a consistent increase of both AHSG mRNA and protein, while FGF23 silencing was followed by opposite effects. Though most of these results were largely affected by the blockage of FGF23 receptors, the role of these receptors in the different experimental sets is still not completely clarified. In addition, we found that FGF23 and AHSG proteins co-localized both in cytoplasm and nucleus, which suggests a possible reciprocal interactivity. Conclusions: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is modulated by FGF23. Since both proteins play important roles in the bone and cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and vascular pathology, in particular in CKD patients, prompting future investigations in this field.",
keywords = "AHSG, Chronic kidney disease, FGF receptor, FGF23, Osteocyte, Vascular calcification",
author = "D. Mattinzoli and Rastaldi, {M. P.} and M. Ikehata and S. Armelloni and C. Pignatari and Giardino, {L. A.} and M. Li and Alfieri, {C. M.} and A. Regalia and D. Riccardi and P. Messa",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.bone.2015.10.008",
language = "English",
volume = "83",
pages = "35--47",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - FGF23-regulated production of Fetuin-A (AHSG) in osteocytes

AU - Mattinzoli, D.

AU - Rastaldi, M. P.

AU - Ikehata, M.

AU - Armelloni, S.

AU - Pignatari, C.

AU - Giardino, L. A.

AU - Li, M.

AU - Alfieri, C. M.

AU - Regalia, A.

AU - Riccardi, D.

AU - Messa, P.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Introduction: AHSG, a serum glycoprotein with recognized anti-calcification activity, has also been suggested to modulate both bone formation and resorption. Though the bulk of AHSG is mostly synthesized in the liver, it has been claimed that also bone cells might produce it. However, the extent of the bone AHSG production and the potential controlling factors remain to be definitively proven.A relevant number of studies support the notion that FGF23, a bone-derived hormone, not only regulates the most important mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, etc.), but might be also involved in cardiovascular (CV) outcome, both in chronic kidney disease (CKD) patients and in the general population. Furthermore, in addition to some direct autocrine and paracrine effects in bone, FGF23 has been suggested to interact with AHSG. In this study we investigated if AHSG is really produced by bone cells, and if its bone production is related and/or controlled by FGF23, using cultured bone cells, according to a new method recently published by our group. Results: Our data show that AHSG is consistently produced in osteocytes and to a far lesser extent in osteoblasts. Both FGF23 addition to the culture medium and its over-expression in osteocytes were associated with a consistent increase of both AHSG mRNA and protein, while FGF23 silencing was followed by opposite effects. Though most of these results were largely affected by the blockage of FGF23 receptors, the role of these receptors in the different experimental sets is still not completely clarified. In addition, we found that FGF23 and AHSG proteins co-localized both in cytoplasm and nucleus, which suggests a possible reciprocal interactivity. Conclusions: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is modulated by FGF23. Since both proteins play important roles in the bone and cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and vascular pathology, in particular in CKD patients, prompting future investigations in this field.

AB - Introduction: AHSG, a serum glycoprotein with recognized anti-calcification activity, has also been suggested to modulate both bone formation and resorption. Though the bulk of AHSG is mostly synthesized in the liver, it has been claimed that also bone cells might produce it. However, the extent of the bone AHSG production and the potential controlling factors remain to be definitively proven.A relevant number of studies support the notion that FGF23, a bone-derived hormone, not only regulates the most important mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, etc.), but might be also involved in cardiovascular (CV) outcome, both in chronic kidney disease (CKD) patients and in the general population. Furthermore, in addition to some direct autocrine and paracrine effects in bone, FGF23 has been suggested to interact with AHSG. In this study we investigated if AHSG is really produced by bone cells, and if its bone production is related and/or controlled by FGF23, using cultured bone cells, according to a new method recently published by our group. Results: Our data show that AHSG is consistently produced in osteocytes and to a far lesser extent in osteoblasts. Both FGF23 addition to the culture medium and its over-expression in osteocytes were associated with a consistent increase of both AHSG mRNA and protein, while FGF23 silencing was followed by opposite effects. Though most of these results were largely affected by the blockage of FGF23 receptors, the role of these receptors in the different experimental sets is still not completely clarified. In addition, we found that FGF23 and AHSG proteins co-localized both in cytoplasm and nucleus, which suggests a possible reciprocal interactivity. Conclusions: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is modulated by FGF23. Since both proteins play important roles in the bone and cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and vascular pathology, in particular in CKD patients, prompting future investigations in this field.

KW - AHSG

KW - Chronic kidney disease

KW - FGF receptor

KW - FGF23

KW - Osteocyte

KW - Vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=84944810461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944810461&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2015.10.008

DO - 10.1016/j.bone.2015.10.008

M3 - Article

AN - SCOPUS:84944810461

VL - 83

SP - 35

EP - 47

JO - Bone

JF - Bone

SN - 8756-3282

ER -